Á lódáil...
Therapy with JAK2 inhibitors for Myeloproliferative Neoplasms
The development of JAK2 inhibitors followed the discovery of activating mutation of JAK2 (JAK2V617F) in patients with classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs). It is now known that mutations activating the JAK-STAT pathway are ubiquitous in Ph-negative MPNs, and...
Na minha lista:
| Foilsithe in: | Hematol Oncol Clin North Am |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
2012
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406395/ https://ncbi.nlm.nih.gov/pubmed/23009939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hoc.2012.07.008 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|